William Blouin

Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Alison J. Moskowitz, Gunjan L. Shah, Heiko Schöder et al. · Journal of Clinical Oncology · 2021 · 199 citations · Full text

Medicine, Oncology, Pharmacology +13

A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas

Alison J. Moskowitz, Paola Ghione, Eric D. Jacobsen et al. · Blood · 2021 · 177 citations · Full text

Medicine, Oncology, Pharmacology +15

The Combination of Duvelisib, a PI3K-δ,γ Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts

Steven M. Horwitz, Alison J. Moskowitz, Eric D. Jacobsen et al. · Blood · 2018 · 40 citations

Pharmacy, Pharmacology, Pharmacotherapy +11

THE COMBINATION OF DUVELISIB AND ROMIDEPSIN (DR) IS HIGHLY ACTIVE AGAINST RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA WITH LOW RATES OF TRANSAMINITIS: FINAL RESULTS

Steven M. Horwitz, Alison J. Moskowitz, Neha Mehta–Shah et al. · Hematological Oncology · 2021 · 23 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Nursing Guidelines for Administration of Immunoglobulin Replacement Therapy

M. Elizabeth M. Younger, Loris Aro, William Blouin et al. · Journal of Infusion Nursing · 2012 · 13 citations

Life Sciences, Advanced Practice Nursing, Immunology +8